Shandong Xinhua (00719) has received the "Drug Registration Certificate" issued by the National Medical Products Administration for the approval of sodium alendronate oral solution.

SHANDONG XINHUA (00719) announced that recently, SHANDONG XINHUA Limited received the "Drug Registration Certificate" for the oral solution of sodium alendronate approved and issued by the National Medical Products Administration. It is reported that the oral solution of sodium alendronate is used for the treatment of osteoporosis in postmenopausal women, to prevent hip and spine fractures (vertebral compression fractures) and to increase bone mass in men with osteoporosis. According to relevant statistics, the sales revenue of sodium alendronate in 2024 in the three main end markets including Chinese public hospitals, public primary medical institutions, and retail pharmacies will reach RMB 720 million.